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Abstract
Motivation
Reliable identification of molecular biomarkers is essential for accurate patient stratifica-
tion. While state-of-the-art machine learning approaches for sample classification continue
to push boundaries in terms of performance, most of these methods are not able to in-
tegrate different data types and lack generalization power, limiting their application in a
clinical setting. Furthermore, many methods behave as black boxes, and we have very
little understanding about the mechanisms that lead to the prediction. While opaqueness
concerning machine behaviour might not be a problem in deterministic domains, in health
care, providing explanations about the molecular factors and phenotypes that are driving
the classification is crucial to build trust in the performance of the predictive system.
Results
We propose Pathway Induced Multiple Kernel Learning (PIMKL), a novel methodology
to reliably classify samples that can also help gain insights into the molecular mechanisms
that underlie the classification. PIMKL exploits prior knowledge in the form of a molecular
interaction network and annotated gene sets, by optimizing a mixture of pathway-induced
kernels using a Multiple Kernel Learning (MKL) algorithm, an approach that has demon-
strated excellent performance in different machine learning applications. After optimizing
the combination of kernels for prediction of a specific phenotype, the model provides a sta-
ble molecular signature that can be interpreted in the light of the ingested prior knowledge
and that can be used in transfer learning tasks.
Contact
mrm@zurich.ibm.com
Keywords: Biological Networks, Pathways, Machine Learning, Patient Stratification, Mul-
tiple Kernel Learning.
1 Introduction
Designing reliable and interpretable predictive models for patient stratification and biomarker
discovery is a daunting challenge in computational biology. A plethora of methods based
on molecular data have been proposed throughout the years, many of which exploit prior
knowledge about the molecular processes involved in the regulation of the phenotype to
be predicted. Prior knowledge is frequently encoded as a molecular interaction network,
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where nodes represent genes or proteins and edges represent relationships between the
connected nodes. Supporting the development of such methods, the number of databases
reporting protein-protein interactions has seen an unprecedented growth in recent years,
and databases such as STRING [46], OmniPath [49], Reactome [12, 17], IntAct [30], MINT
[35], MatrixDB [9], HPRD [31], KEGG [52, 48, 29] or Pathway Commons [7], just to name
a few, provide an incredibly useful resource for designing models informed about the un-
derlying molecular processes.
Several studies have focused on comparing prior knowledge-based classification meth-
ods. For instance, Cun and Fro¨hlich [13] evaluated 14 machine learning approaches to
predict the survival outcome of breast cancer patients. The methods included, among oth-
ers: average pathway expression [22], classification by significant hub genes [47], pathway
activity classification [33], and a series of approaches based on Support Vector Machines
(SVMs), such as network-based SVMs [53], recursive feature elimination SVMs [23], and
graph diffusion kernels for SVMs [43, 20]. The study concluded that, while none of the
evaluated approaches significantly improved classification accuracy, the interpretability of
the gene signatures obtained was greatly enhanced by the integration of prior knowledge.
A more recent benchmarking effort was provided by a collaboration between the Na-
tional Cancer Institute (NCI) and the Dialogue on Reverse Engineering Assessment and
Methods (DREAM) project [11]. The NCI-DREAM challenge aimed to identify the top-
performing methods for predicting therapeutic response in breast cancer cell lines using
genomic, proteomic, and epigenomic data profiles. A total of 44 prediction algorithms were
scored against an unpublished and hidden gold-standard data set. Two interesting conclu-
sions emerged from the challenge. First, all top-performing methods modeled nonlinear re-
lationships and incorporated biological pathway information, and second, performance was
increased by including multiple, independent data sets. Interestingly, the top-performing
methodology, Bayesian Multitask Multiple Kernel Learning, exploited a multiple kernel
learning (MKL) framework [21].
MKL methods aim to model complex and heterogeneous datasets by using a weighted
combination of base kernels. While in more traditional kernel methods the parameters of a
single kernel are optimized during training, in MKL, the weights of each kernel are tuned
during training. Compared to single-kernel methods, the advantages of MKL are two-fold.
First, different kernels can encode various levels of information, e.g. different definitions of
similarity or different types of data, endowing the algorithm with the flexibility required to
model heterogeneous or multi-modal datasets. Second, after optimizing the combination
of kernels, the weights associated with each kernel can provide valuable insights about the
sets of features that are most informative for the classification task at hand.
In this paper, we seek to augment the predictive power and interpretability of MKL
methods, by supplementing them with the use of prior knowledge. Towards this end, we
introduce the Pathway Induced Multiple Kernel Learning (PIMKL), a supervised classi-
fication algorithm for phenotype prediction from molecular data that jointly exploits the
benefits of MKL and prior knowledge ingestion. PIMKL uses an interaction network and
a set of annotated gene sets to build a mixture of pathway-induced kernels from molecular
data, whose mixture is then optimized with an MKL algorithm. After PIMKL is trained,
the weight assigned to each kernel provides information about the importance of the cor-
responding pathway in the mixture. As a result, a molecular signature characterizing the
phenotype of interest is derived.
While there are currently many approaches that take advantage of the known graph
structure of a molecular system [28, 43], or use collections of annotated gene sets as prior
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knowledge to reduce the dimensionality of molecular profiles and enable the analysis of
tumour profiles [37, 8], to our knowledge PIMKL is the first methodology that integrates
both levels of prior knowledge – molecular networks and collections of pathways – with state-
of-the-art machine learning approaches. We demonstrate that the use of MKL enhances
classification performance, and the use of prior knowledge ensures that the results are
interpretable and shed light on the molecular interactions implicated in the phenotype.
This paper is structured as follows. We first describe PIMKL and validate it by predict-
ing disease-free survival for breast cancer samples from multiple cohorts. We benchmark
PIMKL by comparing it with the methods analyzed in [13]. To evaluate its generalization
power, we use a PIMKL-generated molecular signature to predict disease-free survival on
a different dataset, the METABRIC breast cancer cohort [14]. Finally, we test PIMKL
robustness against noise and its capabilities to integrate distinct data types by simultane-
ously using METABRIC gene expression (mRNA) and copy number alteration (CNA) data
for the same classification task. Our analysis suggest that PIMKL provides an extremely
robust approach for the integration of multiple types of data with prior knowledge that can
be successfully applied to a wide range of phenotype prediction problems.
2 Methods
PIMKL is a methodology for phenotype prediction from multi-omic measurements, e.g.
mRNA, CNA, etc, based on the optimization of a mixture of pathway-induced kernels. Such
kernels are generated by exploiting prior knowledge in a dual fashion. First, prior knowledge
is injected in PIMKL in the form of a molecular interaction network, and second, as a set
of annotated gene sets or pathways.
A key aspect of PIMKL is pathway induction, a method to generate similarity functions
using the topological properties of an interaction network. In practice, we use pathway
gene sets with well-defined biological functions to define sub-networks from which we gen-
erate pathway-induced kernels. This mixture of pathway-induced kernels is then optimized
to classify a phenotype of interest, and in doing so, each pathway is assigned a weight
representing its importance to explain the phenotype. The established link between kernels
and pathways enables PIMKL to identify which molecular mechanisms are important for
the prediction of the considered phenotype, as shown in Figure 1.
2.1 Pathway Induction
PIMKL encodes information from the topology of each pathway’s sub-network. The ap-
proach of integrating pathway information into interaction-aware kernel similarity functions
is here termed pathway induction. Specifically, we design kernel functions by utilizing a pos-
itive semidefinite (PSD) matrix that encodes the topological properties of a graph. Given
any PSD matrix M , a valid kernel can be induced through the following weighted inner
product [40]:
k(x, y) = xTMy .
Hence, in order to have a pathway-induced kernel, we only need to define M such as it
encodes the graph topological information of the pathway.
In this work, an encoding based on the symmetric normalized Laplacian matrix is
adopted. Pathways are defined as weighted undirected graphs P = (V,E,W ), with Nv =
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Figure 1: PIMKL concept. Given a network topology describing molecular interactions, relevant sub-
networks can be extracted to generate a mixture of pathway-induced kernels. The combination of kernels
is then optimized to predict a phenotype of interest. The weights of the mixture provide a measurement of
the importance of each pathway, thereby shedding light on the molecular mechanisms that contribute to
the phenotype.
|V | nodes, Ne = |E| edges and a diagonal weight matrix W ∈ RNe×Ne , representing re-
spectively the molecular entities, e.g. genes or proteins, their interactions and the weights
associated with them.
For any pair of samples x, y ∈ RNv , we define a pathway-induced kernel using the
following similarity function:{
kL(x, y) = xTLy = xTSSTy = Π(x)TΠ(y)
S = D− 12SW 12
where L ∈ RNv×Nv , D ∈ RNv×Nv and S ∈ RNv×Ne are respectively the normalized Laplacian,
the diagonal degree matrix and an ordered incidence matrix for graph P associated with a
pathway (see Supplementary S.1 for a detailed explanation about the formulation and the
design of the kernel function).
The normalized Laplacian can be interpreted as a discrete Laplace operator representing
a diffusion process over graph nodes. A pathway induction process based on it introduces a
mapping Π from the original space of the Nv molecular measurements to an Ne-dimensional
feature space, where each pathway interaction is a dimension, and the value along the edge
is the discrete diffusion potential between the nodes that the edge connects. A schematic
illustration of the mapping introduced using pathway induction can be seen in Figure 2.
2.2 Pathway Induced Multiple Kernel Learning
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Figure 2: Pathway induction. Given a
pathway adjacency matrix, it is possible
to map sample measurements from their
original space, the space of the nodes, to
the space of the interactions between the
molecular entities. The example above
shows how the mapping using pathway in-
duction transforms the considered samples.
PIMKL makes use of the concept of pathway induc-
tion, defined in 2.1, to implement a multiple ker-
nel learning classification system. Consider a net-
work that recapitulates a comprehensive set of known
molecular interactions represented by a graph G =
(V,E,W ) with Nv = |V | nodes, Ne = |E| edges and
a set of molecular measurements X ∈ RN×Nv with
associated labels for a relevant phenotype y.
Given a selection of pathways P , e.g. gene sets
from ontologies or inferred via community detection,
it is possible to extract for each pathway p ∈ P ,
a corresponding sub-graph Pp = (V p, Ep,W p) ⊂ G
with Npv = |V p| nodes, Npe = |Ep| edges and a sub-
selection of measurements corresponding to the genes
contained in the pathway Xp ∈ RN×Npv .
For every pathway, a Gram matrix Kp can be
used to represent the pathway-induced kernel, where
Kp is computed for each pair of samples i and j as
follows:
Kpij = kLp(xi, xj) .
In the above equation, xi, xj ∈ RNpv and Lp is the
normalized Laplacian for Pp ∀p ∈ P .
For the problem of finding the optimal mixture
of kernels over the different pathway-induced ker-
nels, any supervised MKL algorithm can be used.
In this work, a custom version of EasyMKL [1] was
implemented as it achieves high performance at a
low computational cost. EasyMKL is based on the
Kernel method for the Optimization of the Margin
Distribution (KOMD) [2] and focuses on optimizing
a linear combination of kernels:
K =
P∑
p=1
wpK
p, wp ≥ 0
In PIMKL, the weights obtained are divided by their sum, as we are interested in evaluating
the relative contribution of each kernel. This normalization does not affect the quality of
the kernel mixture, which is invariant under positive scalar multiplication. In addition, to
account for differences in sub-graph sizes we force the kernel matrices to have equal trace,
ensuring comparable Gram matrices between different pathways.
It is important to note that PIMKL formulation enables a seamless integration of multi-
omics data. Kernels from different data types can be easily generated and added to the
mixture. The same applies to multi-modal data integration: kernels generated from other
data modalities associated with a specific sample, e.g. histopathology images or clinical
records, can be added to the mixture and weighted accordingly to their contribution in the
classification problem.
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3 Results
In the following sections, we discuss the application of PIMKL to different breast can-
cer cohorts. First, in Section 3.1, PIMKL is compared to a previous study by Cun and
Fro¨lich [13] where different algorithms for phenotype prediction and gene selection using
prior knowledge were compared. Later, in Section 3.2, PIMKL is applied to gene expression
and copy number data from the METABRIC cohort [14] with two purposes: first, we aim
to test whether transfer learning between different studies is possible, and, second, we want
to evaluate PIMKL performance in the analysis of multi-omics analysis in the presence of
noise or uninformative data.
3.1 PIMKL on breast cancer microarray cohorts
PIMKL was tested on microarray gene expression data from six breast cancer cohorts (see
Supplementary Table S1 for details about the cohorts). The classification task consisted
in stratifying breast cancer samples according to occurrence of relapse within 5 years. To
ensure the fairest possible comparison, we used the same interaction sources as in the study
by Cun and Fro¨hlich, namely a merge between KEGG pathways and Pathway Commons.
As access to the older release of KEGG is restricted, the most recent versions from both
sources were used. A collection of 50 hallmark gene sets from the Molecular Signatures
Database (MSigDB) version 5.2 [34] was used to define the sub-graphs used for pathway
induction, generating P = 50 kernels. The classification performance was evaluated by
means of the Area Under the receiver operating characterstic Curve (AUC). We closely
followed the same data processing procedures and the cross-validation scheme as proposed
in the original study (for details, see Supplementary Algorithm S1).
The results of PIMKL compared to the 14 algorithms considered by Cun and Fro¨hlich
are reported in Figure 3. Overall AUC values for the 6 cohorts over the cross-validation
rounds for all considered methods are shown in Figure 3a. AUC values for the single cohorts
can be found in Supplementary Figure S1, where PIMKL exhibits the highest median value
and consistently outperforms the other methods or is in the top performers group on single
cohorts.
Results are consistent when other gene sets are used, even when we use randomized
versions of functionally related gene sets (see Supplementary Figure S2). These results
prove that PIMKL performance does not depend on the specific selection of pathways, and
that through the MKL optimization we can identify the informative gene sets in disparate
collections of genes. Notice, however, that while choosing random gene sets does not worsen
PIMKL performance, interpretation of the molecular signatures, as we will discuss next, is
only possible when the sets have a well defined biological function.
As discussed in Section 2, PIMKL generates a molecular signature given by the weighted
contributions of each kernels. Each weight represents the relative importance of each hall-
mark pathway used for pathway induction to explain the phenotype. To evaluate the
stability of the signature, the pathway weight distribution over cross-validation rounds was
analyzed. Our baseline is the case where all kernels have the same weight: wb =
1
P
, repre-
senting a situation where no pathway contributes more than the others to the phenotype
prediction. To find whether a pathway is significant for the phenotype, the distribution of
the kernel weights with median above wb was tested against the baseline using a one-sample
Wilcoxon signed-rank test. p-values at significance level 0.001 were corrected for multiple
testing using Benjamini-Hochberg (for details see Supplementary Figure S3). Pathways
where the significance was achieved in at least four of six cohorts are reported in Figure 3b.
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Interestingly, heme metabolism pathway is significant in all cohorts. This pathway is
involved in the metabolism of heme and erythroblast differentiation. A possible expla-
nation is that heme metabolism might reflect an active vascularization of the samples, a
phenomenon widely observed in cancer progression [24]. A more intriguing hypothesis is a
possible association between elevated heme metabolism and cancer progression, as has been
reported in non-small-cell lung cancer cells and xenograft tumors [26]. It is also interesting
to look at the pathways that are significant in at least five cohorts: KRAS signaling, myoge-
nesis, allograft rejection, coagulation, P53 pathway and peroxisome. All of these pathways
are associated with breast cancer. For instance, activation of KRAS signaling has been
reported to promote the mesenchymal features of basal-type breast cancer [32, 41]. Myoge-
nesis, or the process of formation of muscular tissue, is commonly disrupted in cancer [25].
Allograft rejection might reflect an immune-mediated tumour rejection signature following
administration of immunotherapeutic agents [5]. Several studies have suggested a role for
blood coagulation proteins in tumour progression [36, 6, 18]. P53 is the most commonly
mutated protein in cancer [50, 38]. Finally, peroxisomes are small, membrane-enclosed or-
ganelles that contain enzymes involved in a variety of metabolic reactions, including several
aspects of energy metabolism. Altered peroxisome metabolism has been linked to various
diseases, including cancer [15, 19].
Finally, Figure 4 reports the correlation of the PIMKL molecular signatures estimated
across multiple cohorts and highlights their stability across different studies, suggesting that
a cohort-independent disease free survival signature for breast cancer has been learned.
3.2 PIMKL on METABRIC cohort
To test PIMKL applicability to multi-modal datasets, we used our methodology to predict
disease free survival in the METABRIC breast cancer cohort, consisting of 1890 samples
profiled with Illumina Human v3 microarray data (mRNA) and Affymetrix SNP 6.0 copy
number data (CNA), see Supplementary Table S2 for details.
In order to validate the generalization power of PIMKL-generated molecular signatures,
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Figure 3: PIMKL cross-validation results. (a) Box plots for AUC values over all cohorts for the
methods considered. PIMKL results are reported in red, while other methods’ results are colored in blue.
Box plots are obtained from ten (repeats of) mean AUC values over 10-fold cross-validation splits, see
algorithm S1. (b) Heat map showing significant pathways selected by PIMKL across the different cohorts
considered in the study. Significant pathways are highlighted in red, while non-significant are colored in
blue.
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we first focused on the analysis of METABRIC microarray data. Our hypothesis here is that
the underlying molecular mechanisms associated with disease free survival are the same in
different cohorts and, as such, knowledge learned in one cohort can be transferred to another
one. After computing the pathway-induced kernels with the same procedure adopted in
Section 3.1, a set of pathway weights was defined using the median of the weights obtained
in the six previously analyzed cohorts. Figure 5 shows the results obtained by training a
KOMD classifier using the weights transferred from the six independent cohorts and by
learning METABRIC-specific pathway weights (for details see Supplementary Algorithm
S2). It is evident that both molecular signatures perform very similarly. Indeed, the two
signatures are highly correlated (Pearson correlation ρ = 0.72, p-value = 3.34 · 10−9, Figure
S4). It is important to notice that the variance of the prediction results is also consistently
reduced, probably due to the newer microarray technology used by the METABRIC study.
GSE2034 GSE11121 GSE1456 GSE2990 GSE4922 GSE7390
GSE2034
GSE11121
GSE1456
GSE2990
GSE4922
GSE7390 0.8
0.4
0.0
0.4
0.8
Figure 4: Correlation in molecular signatures. Heat map reporting the correlation of the molecular
signature estimated across multiple cohorts. Correlation values are reported in the lower triangular part of
the heat map (since it is symmetric) on blue to red scale, white squares indicate non significant correlations.
All cohorts exhibit a positive correlation, significant in most cases, proving the stability of the molecular
signature obtained with PIMKL.
To test PIMKL capability to integrate multi-omics data, both the mRNA and CNA
data from the METABRIC cohort were jointly utilized in the same predictive task. A set
of additional kernels were generated using the copy number data and then used in two ways:
First, the CNA kernels were independently optimized with PIMKL, and second, a mixture
of CNA and mRNA kernels were jointly optimized.
From Figure 6, it is evident that the CNA data are not as predictive as mRNA regarding
disease free survival. However, it is interesting to notice that PIMKL is able to discard noisy
kernels – associated with CNA data – to achieve similar levels of performance when using
the more informative mRNA data and when using a mixture of CNA and mRNA data.
This suggests that the application of the proposed algorithm is feasible even when no prior
knowledge about the information content of each single omic type is available.
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Figure 5: PIMKL performance on METABRIC. Box plots of the performance of PIMKL over the six
cohorts used to benchmark the method (left of the dashed vertical line) and its application on METABRIC
for disease free survival prediction (right of the dashed vertical line). Optimized weights at training by
EasyMKL (blue); provided weights from taking the pathway-wise median weights of the six signatures
obtained during benchmarking (red).
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Figure 6: PIMKL performance on METABRIC multi-omics. Box plots for AUC values obtained
applying PIMKL on different data types and their integration. CNA only results are reported in blue,
mRNA ones in green and their integration in red.
4 Discussion
We have presented here PIMKL (Pathway Induced Multiple Kernel Learning), a novel, effec-
tive and interpretable machine learning methodology for phenotype prediction using multi-
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modal molecular data. PIMKL is based on a multiple kernel learning (MKL) framework, a
kernel-based method that has demonstrated excellent capabilities to integrate multi-omics
datasets [11]. In addition, PIMKL also exploits prior knowledge in the form of molecular
interaction networks and sets of annotated pathways with known biological functions to
build a mixture of pathway-induced kernels. The main novelty introduced in this work is
the definition of multiple interaction-aware kernel functions, which enables us to encode in-
formation about the molecular prior knowledge related to a phenotype, and facilitates the
interpretation of the results in terms of known biological functions and/or specific molec-
ular interactions. We achieve this by using such kernels to map samples into the space of
network edges, i.e. molecular interactions, recovering a direct biological interpretation. The
kernel weights are later optimized to classify a phenotype or a clinical variable of interest.
In this work, PIMKL was extensively tested in the context of predicting disease-free
survival from breast cancer samples. We have demonstrated that the resulting weighted
combination of kernels can be interpreted as a phenotypic molecular signature and provides
insights into the underlying molecular mechanisms. As a benchmark, a well-studied set of
cohorts previously analyzed using a range of stratification methods has been adopted [13].
The quality and the stability of the obtained signatures has been thoroughly investigated,
and we have shown that PIMKL outperforms other methods and finds stable molecular
signatures across different breast cancer cohorts. We also investigated the generalization
power of the found signatures by testing them on unseen mRNA breast cancer data from
the METABRIC cohort and the associated disease-free survival data. The obtained results
have confirmed that the algorithm can be used to effectively gain insights into disease
progression and that this knowledge can be transferred to other cohorts without loss of
performance.
Furthermore, PIMKL can be seamlessly applied to integrate data from different omic
layers. Its intrinsic capability to discard noisy molecular features has been demonstrated by
applying it on METABRIC, where it was possible to integrate multiple types of data with
varying predictive power. Even when non-informative data was mixed with informative
data, PIMKL was able to discard uninformative kernels and achieve similar levels of perfor-
mance. Evidently, PIMKL is not restricted to breast cancer, the specific omic data types or
the sources of prior information used in this work. Its application is open to other disease
types using any available combination of data together with any suitable prior network and
sets of genes.
Besides being capable of using different types of prior knowledge, the proposed approach
is also highly flexible with regard to the number and nature of the selected kernels. Indeed,
PIMKL was developed by making use of an efficient implementation of EasyMKL [1], an
extremely scalable MKL algorithm with constant memory complexity in the number of
kernels. This efficiency can potentially allow the user to define smaller pathways, leading
to a more fine-grained characterization and understanding of the molecular mechanisms
involved in disease progression with limited performance drawbacks.
Finally, possible extensions of PIMKL, such as optimizing the kernel mixture using
semi-supervised or unsupervised multiple kernel learning methodologies [39], may help dis-
covery phenotype-independent pathway signatures and will be explored in the future. To
summarize, PIMKL provides a flexible and scalable method to translate prior knowledge
and molecular data into actionable insights in a clinical setting.
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S.1 Pathway induction
Similarity functions can be designed by making use of a PSD matrix to induce a weighted
inner product:
k(x, y) = xTMy ∀x, y ∈ RN
represents a valid kernel if matrix M ∈ RN×N is PSD [40], indeed this ensures the existence
of a matrix U :
M = UTU
φ(x) = Ux
where φ is a mapping describing a transformation in the feature space.
By making use of a PSD matrix encoding the topological properties of a graph repre-
senting a pathway, it’s possible to design interaction-aware kernels.
Let’s consider an undirected graph representing a pathway:
P = (V,E)
with Nv = |V | nodes and Ne = |E| edges representing the genes/proteins and their in-
teractions respectively. Such a graph is defined by a symmetric adjacency matrix A ∈
{0, 1}Nv×Nv :
Aij = 1 ∀(i, j) ∈ E
and its diagonal degree matrix D ∈ RNv×Nv :
Djj =
∑
i
Aij
For such a graph, the Laplacian matrix L ∈ RNv×Nv is computed using the following:
L = D − A
The Laplacian is a PSD matrix and therefore represents a suitable candidate for induction
of a weighted inner product based on a pathway topology. This can be shown by defining
an ordered incidence matrix S ∈ RNv×Ne for P that by construction satisfies the relation
L = SST . As in [3], after introducing an index set E for the edges E, S can be defined as:
Sne =

1 if n = i ∧ i ≤ j
−1 if n = j
0 otherwise
where e ∈ E corresponds to edge (i, j) ∈ E and n ∈ V
1
Moreover, the Laplacian can be interpreted as a discrete Laplace operator. Indicating
with X ∈ RN×Nv a set of N samples, a discrete diffusion process over graph nodes is
described as:
LXT = SSTXT (1)
where the term STXT computes the discrete diffusion potential (a difference) along the
edges and Equation 1 describes how the flow of this potential is effected, aggregating in-
coming and outgoing flows on the nodes.
Decomposing the Laplacian using an ordered incidence matrix shows how samples X
are mapped from the original space with measurements for Nv molecular entities into an
Ne-dimensional feature space, where each interaction from the pathway is a dimension
and the value along the edge is the discrete diffusion potential between respective node’s
measurements.
The inner product in this space is the resulting similarity function defined as:
kL(x, y) = x
TLy = xTSSTy ∀x, y ∈ RNv
Similar considerations can be applied to weighted graphs with non-negative weights.
Given a weighted undirected graph P = (V,E,W ), indicating by W ∈ RNe×Ne its diagonal
weights matrix, the Laplacian L is defined as:
L = SWST
Lij =
{
di −We if i = j
−We otherwise
where e ∈ E corresponds to edge (i, j) ∈ E
To ensure an equal contribution from all the nodes in the considered pathway, the
degree-normalized version of the Laplacian L can be adopted:
L = D− 12SWSTD− 12
Lij =

1− We
di
if i = j and di 6= 0
− We√
didj
if i and j are adjacent
0 otherwise
where e ∈ E corresponds to edge (i, j) ∈ E
This pathway encoding directly leads to the definition of pathway induction used in this
work. Given any two samples measurement x, y ∈ RNv :
kL(x, y) =xTLy =
=xTD−
1
2SWSTD−
1
2y = xT (D−
1
2SW
1
2 )(W
1
2STD−
1
2 )y =
=xTSSTy = Π(x)TΠ(y)
with:
Π(x) =

√
We
xi√
di
if i = j and di 6= 0
√
We(
xi√
di
− xj√
dj
) if i and j are adjacent
0 otherwise
where e ∈ E corresponds to edge (i, j) ∈ E
2
A similar concept was proposed [10] at the complete network level. The normalized
Laplacian was used as a regularizer to constrain the optimization problem when training
an SVM. In PIMKL, we arrive at a similar formulation of the problem by introducing
a feature mapping instead of using the Laplacian as a regularizer. We define a kernel
function which allows easy application to any kernelized method and any further kernel
transformation (e.g: polynomial, Gaussian, etc.). The decomposition of L can be derived
from the graph but is implicit, and can be easily extended to the multiple kernel learning
case, allowing us to work at pathway/sub-network level.
It should be noted that in PIMKL the individual pathway-induced kernels are set to
equal trace (equal average self similarity of the samples) to learn fair relative weights inde-
pendent of the sub-network size.
S.2 Breast cancer microarray cohorts
Table S1: Breast cancer benchmark cohorts. Brief description of sample counts in the different
classes for the cohorts considered in [13] (all Affymetrix Human Genome U133A Array). In GSE4922 and
GSE11121 metastasis free survival (dmfs) is considered, in other cohorts relapse free survival (rfs).
GEOid [4] Patients dmfs/rfs ≤ 5 years dmfs/rfs > 5 years
GSE2034 [51] 286 93 183
GSE1456 [42] 159 34 119
GSE2990 [45] 187 42 116
GSE4922 [27] 249 69 159
GSE7390 [16] 198 56 135
GSE11121 [44] 200 28 154
Table S2: Breast cancer METABRIC cohort. Brief description of sample counts in the different classes
for the considered data types in the METABRIC (Molecular Taxonomy of Breast Cancer International
Consortium) cohort [14].
Data types Patients Recurred/Progressed DiseaseFree
Illumina Human v3 microarray (mRNA) 1890 647 1333
Affymetrix SNP 6.0 copy number (CNA)
Algorithm S2 PIMKL Cross-validation on METABRIC. Cross-Validation on
METABRIC single omics or multi-omics. Given as input: X molecular measurements
comprised of a selection of data types T (CNA, mRNA or both) with related clinical labels
y, a set of P pathways with a respective pathway for each data type in T and λ = 0.2 for
EasyMKL.
1: for 100 folds with 20 samples per class in (Xtrain, ytrain) do
2: for type in T do
3: learn feature-wise normalization on Xtype,train and apply to Xtype,validation
4: train PIMKL(λ) on {kLp(Xtrain, Xtrain) : p ∈ P} and ytrain
5: report kernel weights w
6: report area under the curve for prediction on
∑P
p=1wpkLp(Xtrain, Xvalidation)
3
Algorithm S1 PIMKL Cross-validation on [13]. Cross-validation analysis of PIMKL
for each of the breast cancer cohorts as suggested in [13] (with internal optimization of
parameters). Given as input: X gene expression measurements with related clinical labels
y, a set of P pathways and a set of hyper-parameters Λ = {0, 0.1, 0.3, 0.5, 0.7, 0.9, 1.0}
for EasyMKL.
1: for i← 1, 10 do
2: for (Xtrain, ytrain), (Xvalidation, yvalidation)← stratified 10-fold split X, y do
3: learn feature-wise normalization on Xtrain and apply to Xvalidation
4: for (Xλtrain, y
λ
train), (X
λ
test, y
λ
test)← stratified 3-fold split of Xtrain, ytrain do .
parameter grid search with 3-fold cross-validation
5: for λ ∈ Λ do
6: train PIMKL(λ) on {kLp(Xλtrain, Xλtrain) : p ∈ P} and yλtrain
7: record prediction accuracy on
∑P
p=1 kLp(X
λ
train, X
λ
test)
8: λ∗ ← argmax(mean prediction accuracy over cross-validation)
9: PIMKL(λ∗) on {kLp(Xtrain, Xtrain) : p ∈ P} and ytrain
10: report kernel weights w
11: report area under the curve for prediction on
∑P
p=1wpkLp(Xtrain, Xvalidation)
12: report mean area under the curve over 10-fold splits . for figure S1 and 3a
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Figure S1: PIMKL cross-validation AUC. Box plots of the AUC values for the methods analyzed in
[13] (blue) and PIMKL (red). PIMKL clearly outperforms other methods in four out of six data sets. For
GSE1456 is performing close to other methods average while for GSE11121 is in the top group. Results
are presented as in [13], where each box is drawn from ten (repeats of) mean AUC values over 10-fold
cross-validation splits, see algorithm S1.
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Figure S2: PIMKL cross-validation AUC for different gene sets. Box plots of all 100 AUC values
(overall 600) for pathway induced MKL obtained by algorithm S1 with different gene sets to define the
pathways given the same aforementioned interactions. In addition to the 50 previously introduced hallmark
gene sets, results for 186 KEGG gene sets from the Molecular Signatures Database (MSigDB) version 5.2
[34] and also respective randomized gene sets are reported. For randomization, the same number of gene
sets is created, each set with random size between 50 and 250 genes by sampling from the union of all gene
sets. The quartiles are comparable within each cohort proving the stability of the methods towards gene
sets selection.
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Figure S3: PIMKL cross-validation weights. Significance of weights over 100 cross-validation folds
for the 50 hallmark pathways are reported. Significant pathways are colored in red, while non-significant
in blue.
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Figure S4: Regression between trained and transferred signature. Regression of the pathway
weights of the signature obtained from directly training on METABRIC (median over 100 cross-validation
folds) against the transferred signature obtained from training on six independent cohorts (each median
over 100 cross-validation folds) indicating high correlation of the two signatures.
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